Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma

<p>Eluted tumor-associated antigen-derived peptides.</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Jitske van den Bulk (17142147) (author)
Kolejni autorzy:	Els M.E. Verdegaal (17142150) (author), Manon van der Ploeg (17142153) (author), Marten Visser (17142156) (author), Joana B. Nunes (17142159) (author), Arnoud H. de Ru (17142162) (author), Rayman T.N. Tjokrodirijo (17142165) (author), Marieke E. Ijsselsteijn (17142168) (author), Natasja I. Janssen (17142171) (author), Ruud van der Breggen (17142174) (author), Linda de Bruin (17142177) (author), Pita de Kok (17142180) (author), George M.C. Janssen (17142183) (author), Dina Ruano (17142186) (author), Ellen H.W. Kapiteijn (17142189) (author), Peter A. van Veelen (17142192) (author), Noel F.C.C. de Miranda (17142195) (author), Sjoerd H. van der Burg (15021483) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Immuno-oncology Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy Skin Cancers Melanoma
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Wydane: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Wydane: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Wydane: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Wydane: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
od: Michael Kilian (16697663)
Wydane: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
od: Michael Kilian (16697663)
Wydane: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
od: Michael Kilian (16697663)
Wydane: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
od: Maria Lozano-Rabella (15056515)
Wydane: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
od: Maria Lozano-Rabella (15056515)
Wydane: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
od: Maria Lozano-Rabella (15056515)
Wydane: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Wydane: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Wydane: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Wydane: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Wydane: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Wydane: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Wydane: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Wydane: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
od: Hansol Lee (15054787)
Wydane: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Wydane: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Wydane: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Wydane: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Wydane: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Wydane: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Wydane: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
od: Joseph Toker (15399882)
Wydane: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
od: Ankita Mitra (17141783)
Wydane: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
od: Ankita Mitra (17141783)
Wydane: (2025)

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
od: Ankita Mitra (17141783)
Wydane: (2025)

Supplementary Table S5 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Wydane: (2025)

Supplementary Figure 5 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
od: Wei Liu (20030)
Wydane: (2025)

Supplementary Table S1 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Wydane: (2025)

Supplementary Table S2 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Wydane: (2025)

Supplementary Table S3 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Wydane: (2025)

Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Wydane: (2025)

Supplementary Table S6 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Wydane: (2025)

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
od: Christine Pich-Bavastro (16509238)
Wydane: (2025)

Supplementary Figure S5 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
od: Rohit Thummalapalli (17314483)
Wydane: (2025)

Supplementary Figure 1 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
od: Wei Liu (20030)
Wydane: (2025)

Supplementary Figure 2 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
od: Wei Liu (20030)
Wydane: (2025)

Supplementary Figure 3 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
od: Wei Liu (20030)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_l2aca1p6v1cf0kahugahr2f542